Original scientific paper

Long-Lasting Partial Regression of Glioblastoma Multiforme Achieved by Edotecarin: Case Report

Eduard Vrdoljak
Marijo Boban
Ž Saratlija-Novaković
Josipa Jović

Abstract

We describe the response to a new chemotherapy agent, topoisomerase I inhibitor edotecarin in an 18-year-old woman with recurring glioblastoma. The therapy was administered for 17 months. The radiological partial response and clinical improvement have been achieved, with minor toxicity. Median survival of patients with glioblastoma is 10 months. With edotecarin we have achieved promising result, which should encourage further investigations to develop more efficient therapy for such a deadly disease.

Keywords

edotecarin; glioblastoma multiforme

Hrčak ID:

3113

URI

https://hrcak.srce.hr/3113

Publication date:

15.4.2006.

Visits: 1.028 *